Utilizing AI and Social Media Analytics to Discover Adverse Side Effects of GLP-1 Receptor Agonists
<|reference_start|>Utilizing AI and Social Media Analytics to Discover Adverse Side Effects of GLP-1 Receptor Agonists: Adverse side effects (ASEs) of drugs, revealed after FDA approval, pose a threat to patient safety. To promptly detect overlooked ASEs, we developed a digital health methodology capable of analyzing massive public data from social media, published clinical research, manufacturers' reports, and ChatGPT. We uncovered ASEs associated with the glucagon-like peptide 1 receptor agonists (GLP-1 RA), a market expected to grow exponentially to $133.5 billion USD by 2030. Using a Named Entity Recognition (NER) model, our method successfully detected 21 potential ASEs overlooked upon FDA approval, including irritability and numbness. Our data-analytic approach revolutionizes the detection of unreported ASEs associated with newly deployed drugs, leveraging cutting-edge AI-driven social media analytics. It can increase the safety of new drugs in the marketplace by unlocking the power of social media to support regulators and manufacturers in the rapid discovery of hidden ASE risks.<|reference_end|>
@article{bartal2024utilizing,
    title={Utilizing AI and Social Media Analytics to Discover Adverse Side Effects
  of GLP-1 Receptor Agonists},
    author={Alon Bartal, Kathleen M. Jagodnik, Nava Pliskin, Abraham Seidmann},
    journal={arXiv preprint arXiv:2404.01358},
    year={2024},
    archivePrefix={arXiv},
    eprint={2404.01358},
    primaryClass={q-bio.QM cs.AI cs.CL cs.IR cs.LG cs.SI}
}